Table 6.
Detection of PCs as potential biomarkers for the diagnosis of early-stage NSCLC.
| No. | Biomarker | p value | q value | Fold-change | AUC (95% CI) | Sensitivity (%) | Specificity (%) | Trend (Cancer) |
|---|---|---|---|---|---|---|---|---|
| 1 | PC(17:2/2:0) | 1.86E-05 | 6.38E-04 | 0.51 | 0.183 (0.078–0.288) | 66.7 | 86.7 | down |
| 2 | PC(18:4/3:0) | 1.18E-03 | 6.07E-03 | 0.59 | 0.233 (0.110–0.356) | 66.7 | 83.3 | down |
| 3 | PC(15:0/18:2) | 7.15E-03 | 1.92E-02 | 0.81 | 0.283 (0.147–0.420) | 56.7 | 90.0 | down |
| 4 | PC(16:0/18:3) | 1.13E-03 | 2.27E-02 | 0.63 | 0.218 (0.101–0.335) | 83.8 | 70.0 | down |
| 5 | PC(17:0/18:2) | 5.72E-04 | 4.36E-03 | 0.79 | 0.250 (0.125–0.375) | 70.0 | 73.3 | down |
| 6 | PC(18:2/18:2) | 1.05E-03 | 5.81E-03 | 0.69 | 0.254 (0.128–0.381) | 53.3 | 93.3 | down |
| 7 | PC(16:0/20:3) | 1.42E-03 | 6.48E-03 | 0.65 | 0.252 (0.126–0.378) | 60.0 | 90.0 | down |
| 8 | PC(15:0/22:6) | 4.00E-04 | 3.63E-03 | 0.71 | 0.243 (0.121–0.365) | 53.5 | 90.0 | down |
| 9 | PC(24:4/17:2) | 3.78E-03 | 1.30E-02 | 0.78 | 0.273 (0.139–0.407) | 70.0 | 80.0 | down |
| 10 | PC(15:0/18:1) | 8.26E-03 | 2.07E-02 | 1.64 | 0.717 (0.586–0.848) | 60.0 | 80.0 | up |
| 11 | PC(18:0/16:0) | 5.27E-03 | 1.62E-02 | 1.34 | 0.763 (0.641–0.885) | 73.3 | 76.7 | up |
| 12 | PC(18:0/20:1) | 1.96E-03 | 3.28E-02 | 1.53 | 0.691 (0.556–0.826) | 66.7 | 70.0 | up |
| Panel a | — | — | 0.897 (0.818–0.975) | 90.0 | 76.7 | |||
| Panel b | — | — | 0.811 (0.703–0.919) | 76.7 | 70.0 | |||
| Panel c | — | — | 1.000 (1.000–1.000) | 100 | 100 |
Panel (a): combination of down-regulated PCs; Panel b: combination of up-regulated PCs.
Panel (c): combination of 12 altered PCs.